News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors
Aerie Pharmaceuticals Elects Dr. Gerald D. Cagle to the Company’s Board of Directors Bedminster, NJ, and Research Triangle Park, NC – September 5, 2013 – Aerie Pharmaceuticals, Inc., announced today that Gerald D. Cagle, Ph.D., has been elected to the Company’s Board of
View HTML
Toggle Summary Aerie Pharmaceuticals Elects Murray Goldberg to the Company’s Board of Directors
Aerie Pharmaceuticals Elects Murray Goldberg to the Company’s Board of Directors Bedminster, NJ and Research Triangle Park, NC - August 19, 2013 - Aerie Pharmaceuticals, Inc. announced today that Murray Goldberg has been elected to the Company’s Board of Directors, effective August 19,
View HTML
Toggle Summary Aerie Pharmaceuticals Names Thomas Mitro as President and Chief Operating Officer
Aerie Pharmaceuticals Names Thomas Mitro as President and Chief Operating Officer Bedminster, NJ and Research Triangle Park, NC - August 5, 2013 - Aerie Pharmaceuticals, Inc. announced today that Thomas Mitro has been named President and Chief Operating Officer of the Company. Mr.
View HTML
Toggle Summary Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer
Aerie Pharmaceuticals Names Vicente Anido, Jr., Current Chairman of the Board, as Chief Executive Officer Bedminster, NJ and Research Triangle Park, NC - July 25, 2013 - Aerie Pharmaceuticals, Inc. announced today that Vicente Anido, Jr., Ph.D., Chairman of Aerie’s Board of Directors, has
View HTML
Toggle Summary Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board
Aerie Pharmaceuticals Names Vicente Anido, Jr. as Chairman of the Board, and David Epstein as Chairman of Aerie’s Scientific Advisory Board Bedminster, NJ and Research Triangle Park, NC - April 4, 2013 - Aerie Pharmaceuticals, Inc. announced today that Vicente Anido, Jr., Ph.D., was named
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at 31st Annual J.P. Morgan Healthcare Conference
JPMorgan Healthcare Conference 2013
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma View HTML
Toggle Summary Aerie Pharmaceuticals Appoints Richard J. Rubino as Chief Financial Officer View HTML
Toggle Summary American Journal of Ophthalmology - Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients With Glaucoma and Ocular Hypertension View HTML